Source comparison
Melanotan-1 vs MT-1: Same Peptide, Different Name
The peptide community generates its own mythology. And one of the most persistent is the idea that melanotan-1 and MT-1 are different compounds with distinct effects or potency levels. They're not. Both terms refer to the same molecule: afamelanotide, a 13-ami
This comparison does not assign a generated winner or score.
- The peptide community generates its own mythology. And one of the most persistent is the idea that melanotan-1 and MT-1 are different compounds with distinct effects or potency levels. They're not. Both terms refer to the same molecule: afamelanotide, a 13-amino-acid peptide sequence first synthesized at the University of Arizona in 1984 as part of research into photoprotection and erythropoietic protoporphyria (EPP). The 'MT-1' designation is simply shorthand. A lab abbreviation that stuck as the compound moved from preclinical work into human trials.
- Our team has guided research institutions through peptide sourcing for over a decade. The naming confusion matters because it creates unnecessary hesitation during procurement. Researchers assume they need to choose between variants when they're ordering the same exact sequence.
- What's the difference between melanotan-1 and MT-1?
- There is no difference between melanotan-1 and MT-1. Both names refer to afamelanotide (C78H111N21O19), a synthetic analog of alpha-melanocyte-stimulating hormone. The peptide contains the same 13-amino-acid sequence (Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2) regardless of nomenclature. MT-1 is simply an abbreviated designation used in early research protocols and carried forward into commercial naming conventions.